Editorial Board Members’ Collection Series: SARS-CoV-2 and COVID-19

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Virology".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 2174

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy
Interests: virus evolution; macrophages; HIV pathogenesis; antivirals; HIV chemotherapy; microbicides; viral resistance; neuroAIDS; mechanisms of virus entry; chemokines and chemokine receptors; role of astrocytes and neurons in HIV infection
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Diagnostic and Laboratory Medicine, Bambino Gesù Children’s Hospital and Research Institute, 00146 Rome, Italy
Interests: microbiomics; proteomics; metaproteomics; metabolomics; microbiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

SARS-CoV-2 is the virus responsible for causing COVID-19, a respiratory illness that can range from mild to severe, and in some cases, fatal. Understanding the biology of this virus is key to developing effective treatments and vaccines. Research shows that SARS-CoV-2 primarily spreads through respiratory droplets when an infected person coughs, sneezes, or talks. It can also spread by touching contaminated surfaces and then touching the face. The ongoing global pandemic caused by the novel coronavirus has brought significant challenges to healthcare systems, economies, and societies worldwide. Relationship with bacteriome and virome communities are highlighting the regulation oft he virus infection, the responsiveness to treatment and the effects of the virus onto communities

The collection series will cover a wide range of topics related to SARS-CoV-2 and COVID, including the virology and pathogenesis of the virus, epidemiology and transmission dynamics, clinical manifestations and treatment options, public health interventions, and the socio-economic impact of the pandemic. Experts in the field are welcome to provide their latest research, insights and perspectives

Prof. Dr. Stefano Aquaro
Dr. Lorenza Putignani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SARS-CoV-2
  • COVID-19
  • epidemiology and pathogenesis
  • clinical presentation
  • vaccines
  • variants
  • relationship between gut and respiratory microbiome and SARS-CoV-2

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

14 pages, 2540 KiB  
Article
Reduced Presence of SARS-CoV-2 microRNA-like Small RNA in the Serum of Patients with Post-Acute Sequelae SARS-CoV-2 Infection
by Maria Alfreda Stincarelli, Isabella Abbate, Giulia Matusali, Michele Tanturli, Marta Camici, Rosaria Arvia, Elisabetta Lazzari, Eleonora Cimini, Alessandra Vergori, Fabrizio Maggi and Simone Giannecchini
Microorganisms 2025, 13(1), 126; https://doi.org/10.3390/microorganisms13010126 - 9 Jan 2025
Viewed by 674
Abstract
The mechanisms underlying post-acute sequelae of SARS-CoV-2 infection (PASC) are a topic of debate. This study examined the presence of SARS-CoV-2 microRNA (miRNA)-like small RNAs in extracellular fluids and their potential link to PASC by using a quantitative stem-loop RT-PCR MiRNA assay. Initially, [...] Read more.
The mechanisms underlying post-acute sequelae of SARS-CoV-2 infection (PASC) are a topic of debate. This study examined the presence of SARS-CoV-2 microRNA (miRNA)-like small RNAs in extracellular fluids and their potential link to PASC by using a quantitative stem-loop RT-PCR MiRNA assay. Initially, it was demonstrated that three previously identified SARS-CoV-2 miRNA-like small RNAs, specifically svRNA 1 and 2 and miR-07a, were significantly expressed in infected cells in vitro and released into the supernatant following infection by different SARS-CoV-2 variants. Then, the expression of three SARS-CoV-2 small RNAs was studied in both nasopharyngeal swabs (NPS) and sera from 24 patients at their initial COVID-19 diagnosis (T0) and in sera collected 91 to 193 days post-diagnosis (T1). Notably, 11 out of 24 patients (46%) reported PASC consequences. All NPS samples showed SARS-CoV-2 small RNA expression with an altered cytokine network during acute infection, but it did not correlate with PASC outcomes. Serum samples had similar small RNA statuses, though PASC patients, notably at T1, but not at T0, displayed reduced overall positivity compared to those without PASC. The host target expression of SARS-CoV-2 small RNAs was not significantly different between groups. This suggests a need for further research into SARS-CoV-2 small RNA and its role in viral behavior and PASC consequences. Full article
(This article belongs to the Special Issue Editorial Board Members’ Collection Series: SARS-CoV-2 and COVID-19)
Show Figures

Figure 1

Other

Jump to: Research

61 pages, 3993 KiB  
Systematic Review
COVID-19 Vaccines Effectiveness and Safety in Trinidad and Tobago: A Systematic Review and Meta-Analysis
by Angel Justiz-Vaillant, Kimberly Roopnarine, Shaundell Solomon, Alyssa Phillips, Solange Sandy, Alyssa Subero, Sarah Seepersad, Nicholas Span, Phalmanie Ramnath, Akaasha Ramnarine, Bimala Ramdath, Chelsea Rampaul, Renissa Ramdial, Dana Phagoo, Thalia Ramdhanie, Vinaya Moonilal, Emily-Marie Poliah, Steffan Poonwassie, Karishta Punilal, Sarah Panchoo, Justice Parris, Steven Oudit, Trudy Muir, Johnson Nicholas-Joseph, Bijay Raj Pandit, Sanjeev Pakeerah, Vesham Sookoo, Patrice Richards, Tishia John, Darren Gopaul, Sachin Soodeen, Odette Arozarena-Barbosa, Arlene Williams, Chandrashehkar Unakal, Rodolfo Arozarena Fundora, Reinand Thompson and Patrick Eberechi Akpakaadd Show full author list remove Hide full author list
Microorganisms 2025, 13(1), 135; https://doi.org/10.3390/microorganisms13010135 - 10 Jan 2025
Viewed by 1096
Abstract
This systematic review evaluated the effectiveness and side effects of various COVID-19 vaccines, with a focus on Trinidad and Tobago. The Pfizer-BioNTech and Moderna vaccines demonstrated the highest efficacy, particularly against COVID-19 variants, while Janssen and Sinopharm were comparatively less effective. mRNA vaccines, [...] Read more.
This systematic review evaluated the effectiveness and side effects of various COVID-19 vaccines, with a focus on Trinidad and Tobago. The Pfizer-BioNTech and Moderna vaccines demonstrated the highest efficacy, particularly against COVID-19 variants, while Janssen and Sinopharm were comparatively less effective. mRNA vaccines, such as Pfizer-BioNTech and Oxford-AstraZeneca, were associated with more frequent and severe side effects, including soreness, fever, and cardiovascular issues. The review also identified significant gaps in the current scientific literature regarding COVID-19 vaccination issues in Trinidad and Tobago. These gaps highlight the need for comprehensive research to address vaccination challenges, including public health communication, equitable access, and local perceptions of vaccine safety. This analysis provides a foundation for developing targeted strategies to improve vaccine effectiveness in the region. Full article
(This article belongs to the Special Issue Editorial Board Members’ Collection Series: SARS-CoV-2 and COVID-19)
Show Figures

Figure 1

Back to TopTop